Literature DB >> 20675147

How to use bleomycin A5 for infantile maxillofacial haemangiomas: clinical evaluation of 82 consecutive cases.

Quanfeng Luo1, Fuyun Zhao.   

Abstract

OBJECTIVE: Bleomycin A5 has been reported effective for infantile haemangioma (IH), but the usage and complications were described a little. We have used bleomycin A5 to treat maxillofacial IHs for 15 years. This paper describes the procedures to use bleomycin A5 and avoid its complications based on our clinical practices.
METHODS: Bleomycin A5 (8mg, powder) was mixed with 2% lidocaine (3ml) and dexamethasone (1ml, 5mg), the mixture concentration is 2mg/ml (bleomycin A5). The drug was given by multiple intralesional injections, with the dosage calculated according to the age of the patient and size of the lesion. Cautions were paid to the drug dosage and concentration, as well as the depth of injection. The patients were also given oral prednisone (2-5mg/kg every other day) during proliferating stage.
RESULTS: After treatment with bleomycin A5 in appropriate quantity and concentration, injecting depth, all haemangiomas involuted completely, with smaller lesions showing better recovery of skin colour and less scar formation, and no serious side effects happened.
CONCLUSION: Bleomycin A5 is an effective treatment for IHs. Oral prednisone is necessary for patients at proliferating stage.
Copyright © 2010 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20675147     DOI: 10.1016/j.jcms.2010.06.002

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  9 in total

1.  High-pitch spiral CT with 3D reformation: an alternative choice for imaging vascular anomalies with affluent blood flow in the head and neck of infants and children.

Authors:  H-O Li; R Huo; X-M Wang; G-Q Xu; Y-H Duan; P Nie; X-P Ji; Z-P Cheng; Z-D Xu
Journal:  Br J Radiol       Date:  2015-06-09       Impact factor: 3.039

Review 2.  The changing face of complicated infantile hemangioma treatment.

Authors:  Deanna Menapace; Mario Mitkov; Richard Towbin; Marcia Hogeling
Journal:  Pediatr Radiol       Date:  2016-07-23

3.  Bleomycin loaded magnetite nanoparticles functionalized by polyacrylic acid as a new antitumoral drug delivery system.

Authors:  Yue Xu; Yi Lin; Lin Zhuang; Jiong Lin; Jiahong Lv; Qin Huang; Jiadong Sun
Journal:  Biomed Res Int       Date:  2013-08-05       Impact factor: 3.411

4.  Author's reply: To PMID 22824608.

Authors:  Derrick P Smit; David Meyer
Journal:  Indian J Ophthalmol       Date:  2013-07       Impact factor: 1.848

5.  Proapoptotic effect and the mechanism of action of pingyangmycin on cavernous hemangiomas.

Authors:  Yideng Huang; Ping Li; Siwen Xia; Yang Zhuo; Longjun Wu
Journal:  Exp Ther Med       Date:  2013-11-26       Impact factor: 2.447

6.  Effects of bleomycin A5 on caspase-3, P53, bcl-2 expression and telomerase activity in vascular endothelial cells.

Authors:  Yi-Deng Huang; Ping Li; Xiao Tong; Yue He; Yang Zhuo; Si-Wen Xia; Xing-Hua Luo
Journal:  Indian J Pharmacol       Date:  2015 Jan-Feb       Impact factor: 1.200

7.  Pingyangmycin Pretreatment Influences the Biological Behavior of Ocular Venous Malformation and Relates with Galectin-3 Expression.

Authors:  Jin Li; Jun-Bo Qiao; Qiu-Yu Liu
Journal:  Chin Med J (Engl)       Date:  2017-08-05       Impact factor: 2.628

8.  Periocular capillary hemangioma: management practices in recent years.

Authors:  Jo Anne Hernandez; Audrey Chia; Boon Long Quah; Lay Leng Seah
Journal:  Clin Ophthalmol       Date:  2013-06-21

9.  Intralesional bleomycin injection for periocular capillary hemangiomas.

Authors:  V P Gupta; Pragati Gupta
Journal:  Indian J Ophthalmol       Date:  2013-07       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.